Henry Schein’s (HSIC) Overweight Rating Reiterated at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Henry Schein (NASDAQ:HSICFree Report) in a research report report published on Friday morning, Benzinga reports. They currently have a $86.00 price objective on the stock.

A number of other analysts also recently weighed in on the company. Evercore ISI lifted their price target on Henry Schein from $79.00 to $83.00 and gave the company an in-line rating in a research note on Wednesday, February 28th. Leerink Partnrs restated a market perform rating on shares of Henry Schein in a research note on Monday, February 26th. JPMorgan Chase & Co. lifted their price target on Henry Schein from $82.00 to $88.00 and gave the company an overweight rating in a research note on Wednesday, March 6th. Barrington Research lifted their price target on Henry Schein from $90.00 to $92.00 and gave the company an outperform rating in a research note on Wednesday, May 8th. Finally, UBS Group decreased their price target on Henry Schein from $82.00 to $80.00 and set a neutral rating on the stock in a research note on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Hold and a consensus price target of $81.73.

Read Our Latest Stock Report on Henry Schein

Henry Schein Trading Up 1.1 %

NASDAQ:HSIC opened at $67.26 on Friday. The firm has a market cap of $8.61 billion, a P/E ratio of 22.72, a PEG ratio of 1.64 and a beta of 0.90. The company has a current ratio of 1.75, a quick ratio of 1.02 and a debt-to-equity ratio of 0.47. The stock’s 50 day simple moving average is $70.44 and its 200-day simple moving average is $73.13. Henry Schein has a 12-month low of $60.01 and a 12-month high of $82.63.

Henry Schein (NASDAQ:HSICGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.21 billion. Henry Schein had a return on equity of 13.51% and a net margin of 3.12%. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.21 earnings per share. Equities analysts anticipate that Henry Schein will post 5.17 EPS for the current year.

Institutional Trading of Henry Schein

Several institutional investors and hedge funds have recently made changes to their positions in HSIC. Swedbank AB purchased a new stake in shares of Henry Schein in the first quarter valued at $215,998,000. Boston Partners lifted its position in shares of Henry Schein by 144.1% in the fourth quarter. Boston Partners now owns 2,637,429 shares of the company’s stock valued at $199,393,000 after acquiring an additional 1,556,831 shares in the last quarter. Norges Bank purchased a new stake in shares of Henry Schein in the fourth quarter valued at $111,715,000. Nuance Investments LLC purchased a new stake in shares of Henry Schein in the fourth quarter valued at $103,446,000. Finally, Lazard Asset Management LLC lifted its position in shares of Henry Schein by 1,303.3% in the third quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company’s stock valued at $92,614,000 after acquiring an additional 1,158,451 shares in the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Company Profile

(Get Free Report)

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Featured Articles

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.